Skip to content

Candel Therapeutics

US · CADL #3461 by market cap Listed 2021
5.04 -0.09 -1.75%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 5.01 -2.34%
After-hours 4.99 -0.97%
13.755.045.042026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CADL?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -22.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 17.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -27,739.2% Better than 0%
Net margin -15,035.2% Better than 1%
Return on equity -64.6% Better than 7%
Return on invested capital -44.2% Better than 7%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -61.6% Better than 2%
6-month return -36.9% Better than 14%
12-month return (ex latest month) 84.2% Better than 93%
Distance below 52-week high 64.0% Better than 8%
Financial Health C+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 13.5x Better than 96%
Debt to assets 39.2% Better than 28%
Interest coverage -17.0x Better than 10%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 233.9% Better than 96%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -18.71%
1M -41.67%
3M -59.19%
6M -34.63%
YTD -10.80%
1Y +14.03%
3Y +466.29%
5Y -53.63%

Key statistics

Price & volume

Prev close
5.13
Open
5.00
Day range
4.90 - 5.31
Avg price
5.04
Volume
1.73M
Turnover
8.71M
Amplitude
7.99%
52-week range
4.35 - 14.00

Valuation

P/E
-7.00
P/E (TTM)
-3.29
P/B
3.01
EPS
-0.72
Net profit
-56.48M
Net assets
131.55M

Share structure

Market cap
395.37M
Float cap
345.58M
Shares out
78.45M
Float shares
68.57M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-07-27
52-week range 7% of range
4.35 14.00

64.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-3.37M net over the window

Short interest

Shares short
13.09M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Candel Therapeutics (CADL)?

Candel Therapeutics last traded at 5.04. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Candel Therapeutics's market cap?

About 395.37M.

What is the P/E ratio of Candel Therapeutics?

The trailing twelve-month P/E is -3.29. The Valuation tab shows it against the stock's own five-year range.

Does Candel Therapeutics pay a dividend?

Candel Therapeutics does not currently pay a regular dividend.

Is Candel Therapeutics a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 16.83, which implies 233.9% upside from the current price. This is not investment advice.

What is Candel Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Candel Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.

Candel Therapeutics discussion 0 comments

Add a comment